We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Saliva Specimens Diagnose Respiratory Virus by POC Assay

By LabMedica International staff writers
Posted on 05 Jul 2018
The use of saliva as a specimen for the detection of respiratory viruses has been proposed as an alternative to nasopharyngeal aspirate or nasopharyngeal swab: saliva may have the advantage to cause less discomfort in patients and less risk for healthcare workers.

Automated point-of-care molecular assays have greatly shortened the turnaround time of respiratory virus testing. More...
One of the major bottlenecks now lies at the step of the specimen collection especially in a busy clinical setting. Saliva is a convenient specimen type, which can be provided easily from adult patients.

Scientists from the University of Hong Kong (Pokfulam, Hong Kong) recruited between July and October 2017, 214 patients and carried out a prospective diagnostic validity study comparing the detection rate of respiratory viruses between saliva and nasopharyngeal aspirate (NPA) among adult hospitalized patients using Xpert Xpress Flu/RSV. The cost and time associated with the collection of saliva and nasopharyngeal specimens were also estimated.

The team found that the overall agreement between saliva and NPA were 93.3% (196/210). There was no significant difference in the detection rate of respiratory viruses between saliva and NPA; (69/210 (32.9%) versus 75/210 (35.7%). The overall sensitivity and specificity were 90.8% (81.9-96.2%) and 100% (97.3-100%), respectively, for saliva, and were 96.1% (88.9-99.2%) and 98.5% (94.7-99.8%), respectively, for NPA. The time and cost associated with the collection of saliva were 2.3-fold and 2.6-fold lower, respectively, than those of NPA.

The authors concluded that saliva specimen had high sensitivity and specificity in the detection of respiratory viruses by an automated multiplex Clinical Laboratory Improvement Amendments (CLIA)-waived point-of-care molecular assay when compared with that of NPA. The use of saliva also reduces the time and cost associated with specimen collection. The study was published on June 12, 2018, in the journal Clinical Microbiology and Infection.

Related Links:
University of Hong Kong


New
Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
HPV Test
Allplex HPV28 Detection
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.